Something is shifting in the consulting room. Quietly, without the fanfare of a licensing announcement or a government green paper, a new modality is beginning to find its footing in private practice — one that asks a fundamental question of the therapy profession: what if the greatest barrier to relational healing is not a lack of insight, but a nervous system that is physiologically unable to receive it?
Ketamine-assisted psychotherapy has been gathering momentum in the United Kingdom and across Europe, primarily as an individual intervention for treatment-resistant depression, post-traumatic stress disorder, and anxiety. The clinical evidence base is growing robustly. But a more specialised application is now beginning to emerge, both in published research and in private clinical settings: the use of ketamine as an adjunct to couples therapy.
This article explores the science, the emerging framework, the London context, and the ethical considerations that practitioners working in relational mental health cannot afford to ignore. It is written from the perspective of a clinician with over two decades of psychotherapeutic experience and a deep commitment to evidence-informed, neurodiversity-affirming practice.
What if the greatest barrier to relational healing is not a lack of insight, but a nervous system that is physiologically unable to receive it?
The Relational Crisis Beneath the Surface
Intimate relationship distress is not a niche concern. Research spanning eight decades and drawing on thousands of participants consistently identifies the quality of intimate relationships as one of the most powerful determinants of physical health, mental health, and overall life satisfaction. When relationships falter — and many do, often for years before partners seek professional help — the consequences extend far beyond unhappiness. Relationship dysfunction is associated with significantly elevated rates of depression, anxiety, substance misuse, and even early mortality.
And yet, couples therapy faces a persistent paradox. The evidence base for modalities such as Emotionally Focused Therapy, the Gottman Method, and Cognitive Behavioural Couples Therapy is solid. These approaches work. But they work best when both partners are capable of the emotional regulation, cognitive flexibility, and openness to vulnerability that genuine relational healing demands. For many couples who arrive in a therapist’s office, one or both partners are in a state of chronic defensive arousal — a neurobiological condition, not a moral failing. No amount of skilled facilitation can fully resolve what the body is not yet ready to receive.
This is the clinical gap that ketamine-assisted couples therapy begins to address.
What Is Ketamine-Assisted Couples Therapy?
Ketamine-assisted psychotherapy (KAP) is not simply the administration of a substance alongside a talking therapy session. It is a structured, multi-phase clinical protocol in which carefully calibrated sub-anaesthetic doses of ketamine are used to create a neurobiological state of heightened plasticity, reduced defensive reactivity, and expanded perspective — a state that can then be intentionally channelled into therapeutic work.
For individual work, the mechanism is well documented. Ketamine promotes rapid neuroplasticity through its action on NMDA receptors, increases functional connectivity between brain regions associated with self-reflection and emotional processing, and temporarily disrupts the rigid associative loops that characterise depression, trauma, and anxiety. Unlike classical antidepressants, which may take weeks to produce measurable effects, ketamine can induce profound shifts in psychological state within hours.
When this mechanism is applied to couples work, the implications are striking. A landmark 2024 paper published in Frontiers in Psychiatry by Khalifian and colleagues at the University of California, San Diego, outlined the first comprehensive framework for ketamine-assisted couple therapy. The authors propose that ketamine’s effects — increased neuroplasticity, adaptive dissociation, decreased inhibition, and reduced avoidance — map directly onto the change mechanisms that evidence-based couples therapies seek to activate.
In practical terms, this means that ketamine may help a partner who is chronically defensive to soften their protective structures sufficiently to hear their partner. It may help someone who has been emotionally numbed by years of relational pain to access the empathy and curiosity that therapy requires. It may dissolve the cognitive rigidity that keeps people narrating the same grievances and attributing the same negative intentions to one another, and create — even briefly — a neurobiological window of openness in which new patterns can be established.
Ketamine may help a partner who is chronically defensive to soften their protective structures sufficiently to hear their partner.
Dosing Approaches and the Structure of Treatment
One of the clinically sophisticated aspects of the emerging framework is its acknowledgment that there is no single approach to how ketamine is incorporated into couples work. Different dosing strategies carry different therapeutic affordances, and the choice between them should be guided by the couple’s presentation, relational dynamics, and therapeutic goals.
In what researchers describe as an asymmetric dosing approach, one partner receives their prescribed dose whilst the other remains sober, taking on a supportive witnessing role. This can be particularly powerful where one partner carries a disproportionate burden of trauma or treatment-resistant depression that is directly affecting the relational dynamic. The non-dosing partner’s experience of holding space — of remaining present without the compulsion to fix, argue, or defend — can itself be profoundly therapeutic.
In simultaneous dosing sessions, both partners engage with the ketamine experience concurrently, within a clinically supervised setting. The literature documents reports of heightened feelings of connection and empathy during these sessions, as well as a dissolution of the ego-bound positions that typically fuel conflict. Integration sessions — carried out in the days immediately following the dosing experience — are considered essential. It is in this integration phase that the relational insights accessed during the ketamine state are translated into durable change through structured therapeutic conversation.
The full protocol, as described in the research literature, typically includes: a dyadic assessment session to map relational patterns and identify treatment targets; individual psychiatric and psychological assessments for each partner; preparatory psychotherapy sessions without medication; one or more dosing sessions; and post-session integration therapy. The protocol is not a shortcut to relational healing. It is an intensification of the conditions under which healing becomes possible.
The London Context: A Market on the Cusp
London’s private mental health sector has been quietly watching the development of ketamine-assisted therapy with a mixture of cautious interest and regulatory wariness. The UK landscape is more complex than that of the United States, where ketamine has been legally prescribable by licensed practitioners and used in innovative clinical applications since its reclassification as a Schedule III controlled substance opened the door to broader off-label use.
In the UK, ketamine is currently classified as a Class B controlled substance, and it has not been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for any mental health indication. It can be prescribed off-label by registered medical practitioners for individual patients where clinical need is established — and a small but growing number of private London clinics are doing precisely this. Klearwell, Save Minds, AION Clinic in Islington, Eulas Clinics, and a number of Harley Street-based consultant psychiatrists now offer ketamine-assisted therapy for individuals with treatment-resistant presentations. The clinical experience accumulating within these services is quietly building the case for broader application.
Esketamine, the nasal spray derivative branded as Spravato, received MHRA approval in 2019 but has not been recommended by NICE for routine commissioning. Imperial College London’s research programme (2021 to 2024) produced compelling evidence for the efficacy of repeated KAP sessions in patients with PTSD and complex trauma, adding significant weight to the UK evidence base.
What does not yet exist in London — or, to the best of current knowledge, anywhere in the UK — is a formally offered ketamine-assisted couples therapy programme. The individual KAP sector is established. The couples therapy sector is established. The clinical research bridging the two is now published and peer-reviewed. The pathway to integration is clear in principle. What is required is the clinical infrastructure, the psychiatric partnership, and the therapeutic expertise to make it a reality within an ethically sound and clinically robust framework.
What does not yet exist in London is a formally offered ketamine-assisted couples therapy programme. The pathway is clear. The infrastructure is what is needed.
The Neuroscience of Relational Healing
To understand why ketamine may be particularly valuable in couples work, it is helpful to consider the neuroscience of relational conflict and repair. When we are in conflict with someone to whom we are emotionally attached, the nervous system responds as though under threat. The amygdala — the brain’s threat-detection centre — activates. The prefrontal cortex, which governs nuanced reasoning, perspective-taking, and emotional regulation, becomes less available. We move into survival-oriented modes of communication: defending, withdrawing, attacking, or shutting down.
The clinician Dan Siegel describes this as a state of neural integration breakdown — a collapse in the coordinated functioning of the brain regions that enable reflective, empathic engagement. Attachment theorists would recognise it as the activation of insecure attachment responses: hyperactivation, with its characteristic protest and clinging, or deactivation, with its emotional withdrawal and dismissal. In either case, what the partner experiences as cruelty or indifference is often the involuntary expression of a nervous system in dysregulation.
Standard couples therapy works by creating conditions in which the nervous system can gradually return to a state of safety — through the secure base of the therapeutic relationship, through psychoeducation about relational patterns, and through the slow accumulation of positive interactional experiences. This is meaningful work, and it is efficacious. But it is slow, because the nervous system learns slowly. Ketamine, by temporarily suspending the defensive structures of the ego and facilitating a state of neurological openness, may compress this timeline significantly — not by bypassing the therapeutic process, but by creating the neurobiological preconditions for it to occur more rapidly and more deeply.
Ethical Considerations and Clinical Safeguards
Any serious engagement with ketamine-assisted couples therapy must be anchored in rigorous ethical thinking. This is not a modality that can be offered lightly, and the enthusiasm that surrounds psychedelic-assisted therapies more broadly must not outpace the clinical caution that vulnerable clients deserve.
The first ethical imperative is informed consent, and in couples work it is more complex than in individual therapy. Both partners must independently understand the nature of the intervention, the potential risks, and their right to withdraw without relational consequences. Power imbalances within the relationship — whether related to mental health status, neurodiversity, cultural background, or history of coercion — must be carefully assessed and addressed before any dosing is considered. The therapeutic relationship must be sufficiently established for both partners to feel genuinely safe within the process.
Medical contraindications are significant and must be assessed by a qualified psychiatrist. These include cardiovascular conditions, a personal or family history of psychosis, active substance misuse, and certain neurological conditions. Pregnancy is a clear contraindication. The prescribing and administration of ketamine must be undertaken by a registered medical practitioner within a CQC-regulated environment. A therapist, however experienced, cannot and must not operate outside these boundaries.
The integration phase is not optional. It is, arguably, where the therapeutic work happens most critically. The neurobiological window opened by ketamine is a resource to be used therapeutically, not merely an experience to be had. Without skilled integration — facilitated by a therapist who understands both the relational dynamics and the particular quality of the post-ketamine state — the potential of the intervention is significantly diminished, and the risk of disorientation or relational misattunement is increased.
Finally, practitioners considering this area must attend to the question of their own training and competence. The psychedelic-assisted therapy field is developing rapidly, and the training standards, accreditation pathways, and professional frameworks are still being established in the UK. Clinicians have a responsibility to engage with this process rather than to outrun it.
What This Means for Relational Mental Health Practice
The emergence of ketamine-assisted couples therapy represents, in this clinician’s view, not a departure from the relational therapeutic tradition but a deepening of it. The field has always understood that insight alone does not heal. That knowing what is wrong is not the same as being able to change it. That the body holds what the mind knows intellectually but cannot yet feel. The integration of pharmacological neuroplasticity tools with the sophisticated relational frameworks developed over decades of clinical research is not a contradiction — it is a logical extension of what the evidence has long been pointing towards.
For London-based therapists and practice leaders, the implications are several. Those who practise couples therapy and who work in collaborative or multi-disciplinary settings are well placed to begin building the knowledge base, the clinical partnerships, and the referral frameworks that will be needed as this modality develops. Those who maintain relationships with consultant psychiatrists — particularly those experienced in ketamine-assisted therapy — are particularly advantageously positioned.
The population most likely to benefit is already present in private practice: couples where one or both partners carry significant trauma histories; couples where emotional avoidance or shutdown has made traditional couples therapy feel stalled; couples where a neurodivergent profile in one or both partners affects emotional regulation and relational attunement in ways that standard approaches do not fully address. In a city as demographically complex and clinically sophisticated as London, the demand for this kind of integrative, evidence-led relational care is considerable.
The integration of pharmacological neuroplasticity tools with relational therapeutic frameworks is not a contradiction — it is a logical extension of what the evidence has long been pointing towards.
Conclusion
Ketamine-assisted couples therapy is not yet a mainstream offering in London. The regulatory environment is more restrictive than in the United States, the training infrastructure is still developing, and the clinical community is, rightly, proceeding with appropriate care. But the evidence is accumulating, the interest is growing, and the clinical need is undeniable.
For practitioners committed to offering the most effective care available to couples in distress, the question is no longer whether this modality will arrive in London. It is a matter of when, and whether those who shape its arrival will do so with the rigour, the ethics, and the deep clinical respect for the relational field that such a significant development demands.
London Trusted Therapy will continue to monitor developments in this space closely, to engage with the emerging research, and to explore how integrative models of relational care can be developed within a framework of clinical excellence and ethical integrity.
About the Author
Dr Olena Edwards-Skadowska is a psychotherapist specialising in neurodiversity with over 20 years of clinical experience. She is the Founder and CEO of London Trusted Therapy, a multi-disciplinary private practice based at 115A Harley Street, London. She is autistic herself, diagnosed in her 50s, and brings her lived experience directly into her clinical and leadership work.
She is the author of Anxie the Hedgehog (2024) and is currently completing her second book, The Relief and the Grief: Understanding Late Autism Diagnosis in Women. She holds a PhD, MA, PGDip, is MBACP Accredited, and is a Full Member of the British Psychological Society (FMBPsS).
